Continuous plasmafiltration in sepsis syndrome

被引:156
作者
Reeves, JH
Butt, WW
Shann, F
Layton, JE
Stewart, A
Waring, PM
Presneill, JJ
机构
[1] Royal Childrens Hosp, Intens Care Unit, Parkville, Vic 3052, Australia
[2] Ludwig Inst Canc Res, Melbourne Tumour Biol Branch, Parkville, Vic, Australia
[3] Bernard OBrien Inst Microsurg, Fitzroy, Vic, Australia
[4] Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Canc Res Unit, Parkville, Vic 3050, Australia
[5] Royal Melbourne Hosp, Intens Care Unit, Parkville, Vic 3050, Australia
关键词
sepsis; randomized; controlled trial; mortality; cytokines; plasmapheresis; multiple organ failure; acute phase proteins; albumins; eicosanoids; inflammation;
D O I
10.1097/00003246-199910000-00003
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Objective: To assess the effect of plasmafiltration (PF) on biochemical markers of inflammation, cytokines, organ dysfunction, and 14-day mortality in human sepsis. Design: Multicenter, prospective, randomized, controlled clinical trial. Setting: Seven university-affiliated intensive care units. Patients: Thirty patients (22 adults, eight children) with new (<24 hrs) clinical evidence of infection and sepsis syndrome were enrolled. Fourteen of 30 (nine adults, five children) were randomized to PF. Interventions: All patients received protocol-driven supportive intensive care, and those randomized to PF received continuous plasma exchange for 34 hrs using a hollow-fiber plasma filter. Measurements and Main Results: Illness severity and risk of death were calculated with the Pediatric Risk of Mortality (children) and the Acute Physiology and Chronic Health Evaluation II (adults) scales. Plasma samples (0, 6, 24, and 48 hrs) were assayed for acute-phase proteins (albumin, globulin, C-reactive protein, alpha(1)-antitrypsin, haptoglobin), inflammatory mediators (complement fragment C-3, thromboxane B-2), and cytokines (interleukin-g, granulocyte colony-stimulating factor, leukemia inhibitory factor). Sieving coefficients were estimated from filtrate concentrations at 3 hrs. The two groups were matched for incidence of septic shock (13 of 14 vs. 11 of 16), refractory shock (three of 14 vs. six of 16), bacteremia (six of 14 vs. five of 16), severity of illness, and calculated risk of death (0.68 vs. 0.64). There was no difference in mortality. Eight of 14 PF patients (57%) and eight of 16 controls (50%) survived for 14 days (p = .73, Fisher's exact test). Multiple logistic regression revealed age (odds ratio, 16.4:1; 95% confidence interval, 2.12-infinity) and shock (10.6:1; 1.32-infinity) as significant predictors of death; plasmafiltration was associated with a nonsignificant reduction in the risk of death (odds ratio, 1.78:1; 95% confidence interval, 0.20-18.1). The mean (so) number of organs failing in the first 7 days in the PF group was 2.57 (0.94) vs. 2.94 (0.85) in controls (p = .37, Mann-Whitney U test). Both groups had similarly elevated plasma concentrations of all inflammatory mediators except complement fragment C-3 at study entry. Leukemia inhibitory factor was detectable in four patients only. PF did not influence mean concentrations of interleukin-6, granulocyte colony-stimulating factor, thromboxane B-2 total white cell count, neutrophil count, or platelet count, but it was associated with significant reductions of alpha(1)-antitrypsin, haptoglobin, G-reactive protein, and complement fragment C-3 in the first 6 hrs (p < .05). The sieving coefficients for all inflammatory mediators approached unity. Conclusions: PF caused a significant attenuation of the acute-phase response in sepsis. There was no significant difference in mortality, but there was a trend toward fewer organs failing in the PF group that suggests that this procedure might be beneficial.
引用
收藏
页码:2096 / 2104
页数:9
相关论文
共 65 条
[1]  
[Anonymous], 1982, LANCET, V2, P1025
[2]   CONTINUOUS ARTERIOVENOUS HEMOFILTRATION AND RESPIRATORY-FUNCTION IN MULTIPLE ORGAN SYSTEMS FAILURE [J].
BAGSHAW, ONT ;
ANAES, FRC ;
HUTCHINSON, A .
INTENSIVE CARE MEDICINE, 1992, 18 (06) :334-338
[3]  
Bellomo R, 1995, New Horiz, V3, P732
[4]   PROSTACYCLIN AND THROMBOXANE-A2 FORMATION IS INCREASED IN HUMAN SEPSIS SYNDROME - EFFECTS OF CYCLOOXYGENASE INHIBITION [J].
BERNARD, GR ;
REINES, HD ;
HALUSHKA, PV ;
HIGGINS, SB ;
METZ, CA ;
SWINDELL, BB ;
WRIGHT, PE ;
WATTS, FL ;
VRBANAC, JJ .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1991, 144 (05) :1095-1101
[5]   MENINGOCOCCAL SEPTICEMIA TREATED WITH COMBINED PLASMAPHERESIS AND LEUKAPHERESIS OR WITH BLOOD-EXCHANGE [J].
BJORVATN, B ;
BJERTNAES, L ;
FADNES, HO ;
FLAEGSTAD, T ;
GUTTEBERG, TJ ;
KRISTIANSEN, BE ;
PAPE, J ;
REKVIG, OP ;
OSTERUD, B ;
AANDERUD, L .
BMJ-BRITISH MEDICAL JOURNAL, 1984, 288 (6415) :439-441
[6]   A 2ND LARGE CONTROLLED CLINICAL-STUDY OF E5, A MONOCLONAL-ANTIBODY TO ENDOTOXIN - RESULTS OF A PROSPECTIVE, MULTICENTER, RANDOMIZED, CONTROLLED TRIAL [J].
BONE, RC ;
BALK, RA ;
FEIN, AM ;
PERL, TM ;
WENZEL, RP ;
REINES, HD ;
QUENZER, RW ;
IBERTI, TJ ;
MACINTYRE, N ;
SCHEIN, RMH ;
TRENHOLME, G ;
NIEDERMAN, M ;
CHALFIN, D ;
ABALOS, A ;
OROPELLO, J ;
EMPSON, P ;
CAMINITII, S ;
GREENMAN, R ;
BOOTH, F ;
PLOUFFE, J ;
RUSSELL, J ;
GIANAKOPOULOS, G ;
IANNINI, P ;
HINDES, R ;
COBLENS, K ;
KOHLER, R ;
MARTIN, M ;
BERNARD, G ;
EDWARDS, J ;
CRISLIP, M ;
FILLER, S ;
NASRAWAY, SA ;
SIGEL, PK ;
SOTTILE, FD ;
MARTIN, DH ;
DEBOISBLANC, BP ;
CHANDRASEKAR, PH ;
BROUGHTON, WA ;
MIDDLETON, RM ;
SEIBERT, AF ;
EMMANUEL, G ;
LIE, TH ;
ANDERSON, CLV ;
PANKEY, GA ;
ANDERSON, P ;
OLSEN, K ;
SANPEDRO, GS ;
GRAHAM, D ;
GROSSMAN, J ;
WELS, PB .
CRITICAL CARE MEDICINE, 1995, 23 (06) :994-1006
[7]   AMERICAN-COLLEGE OF CHEST PHYSICIANS SOCIETY OF CRITICAL CARE MEDICINE CONSENSUS CONFERENCE - DEFINITIONS FOR SEPSIS AND ORGAN FAILURE AND GUIDELINES FOR THE USE OF INNOVATIVE THERAPIES IN SEPSIS [J].
BONE, RC ;
BALK, RA ;
CERRA, FB ;
DELLINGER, RP ;
FEIN, AM ;
KNAUS, WA ;
SCHEIN, RMH ;
SIBBALD, WJ ;
ABRAMS, JH ;
BERNARD, GR ;
BIONDI, JW ;
CALVIN, JE ;
DEMLING, R ;
FAHEY, PJ ;
FISHER, CJ ;
FRANKLIN, C ;
GORELICK, KJ ;
KELLEY, MA ;
MAKI, DG ;
MARSHALL, JC ;
MERRILL, WW ;
PRIBBLE, JP ;
RACKOW, EC ;
RODELL, TC ;
SHEAGREN, JN ;
SILVER, M ;
SPRUNG, CL ;
STRAUBE, RC ;
TOBIN, MJ ;
TRENHOLME, GM ;
WAGNER, DP ;
WEBB, CD ;
WHERRY, JC ;
WIEDEMANN, HP ;
WORTEL, CH .
CRITICAL CARE MEDICINE, 1992, 20 (06) :864-874
[8]   A CONTROLLED CLINICAL-TRIAL OF HIGH-DOSE METHYLPREDNISOLONE IN THE TREATMENT OF SEVERE SEPSIS AND SEPTIC SHOCK [J].
BONE, RC ;
FISHER, CJ ;
CLEMMER, TP ;
SLOTMAN, GJ ;
METZ, CA ;
BALK, RA .
NEW ENGLAND JOURNAL OF MEDICINE, 1987, 317 (11) :653-658
[9]   SEPSIS SYNDROME - A VALID CLINICAL ENTITY [J].
BONE, RC ;
FISHER, CJ ;
CLEMMER, TP ;
SLOTMAN, GJ ;
METZ, CA ;
BALK, RA .
CRITICAL CARE MEDICINE, 1989, 17 (05) :389-393